Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APEX-AMI: Pexelizumab in Acute Myocardial Infarction
NCT00091637Phase 3Completed
- Sponsor
- Procter & Gamble
- Start
- Apr 2004
- Primary completion
- May 2007
- Modality
- Antibody Fragments, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in acute myocardial infarction (AMI) comparing Placebo with Pexelizumab (2 arms). Primary endpoint: Reduction of all causes of mortality at 30 days. Started Apr 2004; status: completed.
02
Drugs
pexelizumab
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT00091637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00091637.